The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease

Indication of anti-TNFα monoclonal antibodies

Tadakazu Hisamatsu, Fumiaki Ueno, Takayuki Matsumoto, Kiyonori Kobayashi, Kazutaka Koganei, Reiko Kunisaki, Fumihito Hirai, Masakazu Nagahori, Mitsunobu Matsushita, Kenji Kobayashi, Mitsumasa Kishimoto, Mitsuhiro Takeno, Masanori Tanaka, Nagamu Inoue, Toshifumi Hibi

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Background: Clinical evidence regarding intestinal Behçet's disease (BD) management is lacking and intestinal lesions are a poor prognostic factor. In 2007, the Japan consensus statement for diagnosis and management of intestinal BD was developed. Recently, the efficacy of anti-tumor necrosis factor (TNF)α monoclonal antibodies (mAbs), and infliximab (IFX) was reported and adalimumab (ADA) was approved for intestinal BD in Japan. This study renewed consensus-based practice guidelines for diagnosis and treatment of intestinal BD focusing on the indication of anti-TNFα mAbs. Methods: An expert panel of Japanese gastroenterology and rheumatology specialists was involved. Clinical statements for ratings were extracted from the literature, a professional group survey, and by an expert panel discussion, which rated clinical statements on a nine-point scale. After the first round of ratings, a panelist meeting discussed areas of disagreement and clarified areas of uncertainty. The list of clinical statements was revised after the panelist meeting and a second round of ratings was conducted. Results: Fifteen relevant articles were selected. Based on the first edition consensus statement, improved clinical statements regarding indications for anti-TNFα mAbs use were developed. After a two-round modified Delphi approach, the second edition of consensus statements was finalized. Conclusions: In addition to standard therapies in the first edition, anti-TNFα mAbs (ADA and IFX) should be considered as a standard therapy for intestinal BD. Colchicines, thalidomide, other pharmacological therapy, endoscopic therapy, and leukocytapheresis were deemed experimental therapies.

Original languageEnglish
Pages (from-to)156-162
Number of pages7
JournalJournal of Gastroenterology
Volume49
Issue number1
DOIs
Publication statusPublished - 2014 Jan

Fingerprint

Intestinal Diseases
Tumor Necrosis Factor-alpha
Monoclonal Antibodies
Japan
Leukapheresis
Therapeutics
Investigational Therapies
Thalidomide
Colchicine
Rheumatology
Gastroenterology
Disease Management
Practice Guidelines
Uncertainty
Pharmacology

Keywords

  • Anti-TNFα mAb
  • Consensus statements
  • Intestinal Behçet's disease

ASJC Scopus subject areas

  • Gastroenterology

Cite this

The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease : Indication of anti-TNFα monoclonal antibodies. / Hisamatsu, Tadakazu; Ueno, Fumiaki; Matsumoto, Takayuki; Kobayashi, Kiyonori; Koganei, Kazutaka; Kunisaki, Reiko; Hirai, Fumihito; Nagahori, Masakazu; Matsushita, Mitsunobu; Kobayashi, Kenji; Kishimoto, Mitsumasa; Takeno, Mitsuhiro; Tanaka, Masanori; Inoue, Nagamu; Hibi, Toshifumi.

In: Journal of Gastroenterology, Vol. 49, No. 1, 01.2014, p. 156-162.

Research output: Contribution to journalArticle

Hisamatsu, T, Ueno, F, Matsumoto, T, Kobayashi, K, Koganei, K, Kunisaki, R, Hirai, F, Nagahori, M, Matsushita, M, Kobayashi, K, Kishimoto, M, Takeno, M, Tanaka, M, Inoue, N & Hibi, T 2014, 'The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease: Indication of anti-TNFα monoclonal antibodies', Journal of Gastroenterology, vol. 49, no. 1, pp. 156-162. https://doi.org/10.1007/s00535-013-0872-4
Hisamatsu, Tadakazu ; Ueno, Fumiaki ; Matsumoto, Takayuki ; Kobayashi, Kiyonori ; Koganei, Kazutaka ; Kunisaki, Reiko ; Hirai, Fumihito ; Nagahori, Masakazu ; Matsushita, Mitsunobu ; Kobayashi, Kenji ; Kishimoto, Mitsumasa ; Takeno, Mitsuhiro ; Tanaka, Masanori ; Inoue, Nagamu ; Hibi, Toshifumi. / The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease : Indication of anti-TNFα monoclonal antibodies. In: Journal of Gastroenterology. 2014 ; Vol. 49, No. 1. pp. 156-162.
@article{4a21634785934aa19ad1e27593e69480,
title = "The 2nd edition of consensus statements for the diagnosis and management of intestinal Beh{\cc}et's disease: Indication of anti-TNFα monoclonal antibodies",
abstract = "Background: Clinical evidence regarding intestinal Beh{\cc}et's disease (BD) management is lacking and intestinal lesions are a poor prognostic factor. In 2007, the Japan consensus statement for diagnosis and management of intestinal BD was developed. Recently, the efficacy of anti-tumor necrosis factor (TNF)α monoclonal antibodies (mAbs), and infliximab (IFX) was reported and adalimumab (ADA) was approved for intestinal BD in Japan. This study renewed consensus-based practice guidelines for diagnosis and treatment of intestinal BD focusing on the indication of anti-TNFα mAbs. Methods: An expert panel of Japanese gastroenterology and rheumatology specialists was involved. Clinical statements for ratings were extracted from the literature, a professional group survey, and by an expert panel discussion, which rated clinical statements on a nine-point scale. After the first round of ratings, a panelist meeting discussed areas of disagreement and clarified areas of uncertainty. The list of clinical statements was revised after the panelist meeting and a second round of ratings was conducted. Results: Fifteen relevant articles were selected. Based on the first edition consensus statement, improved clinical statements regarding indications for anti-TNFα mAbs use were developed. After a two-round modified Delphi approach, the second edition of consensus statements was finalized. Conclusions: In addition to standard therapies in the first edition, anti-TNFα mAbs (ADA and IFX) should be considered as a standard therapy for intestinal BD. Colchicines, thalidomide, other pharmacological therapy, endoscopic therapy, and leukocytapheresis were deemed experimental therapies.",
keywords = "Anti-TNFα mAb, Consensus statements, Intestinal Beh{\cc}et's disease",
author = "Tadakazu Hisamatsu and Fumiaki Ueno and Takayuki Matsumoto and Kiyonori Kobayashi and Kazutaka Koganei and Reiko Kunisaki and Fumihito Hirai and Masakazu Nagahori and Mitsunobu Matsushita and Kenji Kobayashi and Mitsumasa Kishimoto and Mitsuhiro Takeno and Masanori Tanaka and Nagamu Inoue and Toshifumi Hibi",
year = "2014",
month = "1",
doi = "10.1007/s00535-013-0872-4",
language = "English",
volume = "49",
pages = "156--162",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease

T2 - Indication of anti-TNFα monoclonal antibodies

AU - Hisamatsu, Tadakazu

AU - Ueno, Fumiaki

AU - Matsumoto, Takayuki

AU - Kobayashi, Kiyonori

AU - Koganei, Kazutaka

AU - Kunisaki, Reiko

AU - Hirai, Fumihito

AU - Nagahori, Masakazu

AU - Matsushita, Mitsunobu

AU - Kobayashi, Kenji

AU - Kishimoto, Mitsumasa

AU - Takeno, Mitsuhiro

AU - Tanaka, Masanori

AU - Inoue, Nagamu

AU - Hibi, Toshifumi

PY - 2014/1

Y1 - 2014/1

N2 - Background: Clinical evidence regarding intestinal Behçet's disease (BD) management is lacking and intestinal lesions are a poor prognostic factor. In 2007, the Japan consensus statement for diagnosis and management of intestinal BD was developed. Recently, the efficacy of anti-tumor necrosis factor (TNF)α monoclonal antibodies (mAbs), and infliximab (IFX) was reported and adalimumab (ADA) was approved for intestinal BD in Japan. This study renewed consensus-based practice guidelines for diagnosis and treatment of intestinal BD focusing on the indication of anti-TNFα mAbs. Methods: An expert panel of Japanese gastroenterology and rheumatology specialists was involved. Clinical statements for ratings were extracted from the literature, a professional group survey, and by an expert panel discussion, which rated clinical statements on a nine-point scale. After the first round of ratings, a panelist meeting discussed areas of disagreement and clarified areas of uncertainty. The list of clinical statements was revised after the panelist meeting and a second round of ratings was conducted. Results: Fifteen relevant articles were selected. Based on the first edition consensus statement, improved clinical statements regarding indications for anti-TNFα mAbs use were developed. After a two-round modified Delphi approach, the second edition of consensus statements was finalized. Conclusions: In addition to standard therapies in the first edition, anti-TNFα mAbs (ADA and IFX) should be considered as a standard therapy for intestinal BD. Colchicines, thalidomide, other pharmacological therapy, endoscopic therapy, and leukocytapheresis were deemed experimental therapies.

AB - Background: Clinical evidence regarding intestinal Behçet's disease (BD) management is lacking and intestinal lesions are a poor prognostic factor. In 2007, the Japan consensus statement for diagnosis and management of intestinal BD was developed. Recently, the efficacy of anti-tumor necrosis factor (TNF)α monoclonal antibodies (mAbs), and infliximab (IFX) was reported and adalimumab (ADA) was approved for intestinal BD in Japan. This study renewed consensus-based practice guidelines for diagnosis and treatment of intestinal BD focusing on the indication of anti-TNFα mAbs. Methods: An expert panel of Japanese gastroenterology and rheumatology specialists was involved. Clinical statements for ratings were extracted from the literature, a professional group survey, and by an expert panel discussion, which rated clinical statements on a nine-point scale. After the first round of ratings, a panelist meeting discussed areas of disagreement and clarified areas of uncertainty. The list of clinical statements was revised after the panelist meeting and a second round of ratings was conducted. Results: Fifteen relevant articles were selected. Based on the first edition consensus statement, improved clinical statements regarding indications for anti-TNFα mAbs use were developed. After a two-round modified Delphi approach, the second edition of consensus statements was finalized. Conclusions: In addition to standard therapies in the first edition, anti-TNFα mAbs (ADA and IFX) should be considered as a standard therapy for intestinal BD. Colchicines, thalidomide, other pharmacological therapy, endoscopic therapy, and leukocytapheresis were deemed experimental therapies.

KW - Anti-TNFα mAb

KW - Consensus statements

KW - Intestinal Behçet's disease

UR - http://www.scopus.com/inward/record.url?scp=84895076984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895076984&partnerID=8YFLogxK

U2 - 10.1007/s00535-013-0872-4

DO - 10.1007/s00535-013-0872-4

M3 - Article

VL - 49

SP - 156

EP - 162

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - 1

ER -